Verastem (VSTM) Tops Q3 EPS by 11c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/23/2026
- Nasdaq reaches record high close, AI stocks rally
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
Verastem Oncology Reports Third Quarter 2019 Financial Results and Recent Company Progress
October 29, 2019 4:17 PM EDTCompany Reports $9 Million in Total Revenue, including $4.0 Million in Net Product Revenue from COPIKTRA®; Reaffirms FY2019 Revenue Guidance
Cash, Cash Equivalents and Short-Term Investments of $160.2 Million as of September 30, 2019
Company to Streamline Organization and Reduce Operating Expenses by $25 Million in 2020
Company to Host Conference Call Today at 4:30 PM ET
BOSTON--(BUSINESS WIRE)-- Verastem, Inc. (Nasdaq: VSTM), operating as Verastem Oncology (or the Company), focused on developing and commercializing medicines seeking to improve the survival and quality of... More
